SureTrader
Home > Boards > Free Zone > User's Groups > "Savvy Trades and Investments”

SRTS...2018 sleeper. Opened the year @ $5.22...Sensus Healthcare

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
2morrowsGains Member Profile
Member Level 
Followed By 69
Posts 5,167
Boards Moderated 0
Alias Born 01/16/05
160x600 placeholder
2morrowsGains Member Level  Wednesday, 01/03/18 07:24:25 AM
Re: 2morrowsGains post# 41043
Post # of 43845 
SRTS...2018 sleeper. Opened the year @ $5.22...Sensus Healthcare is an approx 5 yr old company that went public last year. Not profitable...yet. Could see an accretive acquisition along w/ an offering before Q1 is over. Already has FDA approval (SRT-100) for treating skin cancer and keloids in the US, China, and Mexico. Sensus also submitted a product to FDA approx a month ago which will allow for treatment of psoriasis.
The kicker and thing to watch for in 2018, is the FDA submission and approval of Sensus Healthcare's Intraoperative Radiation Therapy (IORT) device. This will be a bonanza and will drive the stock price to new highs (IMO). Sensus is hoping to have the device submitted to FDA within the next month and approval sometime before year end...

Repost...
"SRTS...Young company not profitable yet, but has high gross margins with no long term debt. They are rapidly increasing their sales, sales force and presence worldwide. Sensus Healthcare is a company w/ a proprietary non-invasive way to treat non-melanoma skin cancers, keloids, and possibly psoriasis, breast cancer, and more. Stay tuned."

From the 2017 Q3 cc...
- "What I can tell you is that things are moving along as scheduled. So at current, we are building a system that is just about completed so that we can start its initial testing. And once we're comfortable with the product being able to pass any and all tests that are going to be required by the FDA, that's when we'll start the paperwork for the submission. So part of the reason why we've had such expense in R&D is, this was a product that was scheduled to come out maybe at the end of 2018. And if we can get it approved before the middle of next year, that just gives us significant runway to get some sales in-house because you have to keep in mind that this is a product that's going to be $800,000 to $900,000. So it's going to have significant revenue impact on the company, BUT IT'S GOING TO HAVE EVEN MORE SIGNIFICANT IMPACT IN THE TREATMENT OF PATIENTS. And that's what we're really excited about. THIS IS A GAME CHANGER AND A LIFESAVER FOR PEOPLE THAT HAVE BREAST CANCER. AND IT'S ALSO GOING TO APPLY TO CERTAIN HEAD AND NECK CANCERS, COLORECTAL, AND VAGINAL CANCERS. These things are what they call orphan cancers, and this is something that is going to be beneficial in those areas as well."
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=136141511&txt2find=srts

Sensus' IORT device has the potential to drastically change the landscape of how breast cancer is treated. In a nutshell, a 3-5 minute procedure done with Sensus Healthcare's 30" x 30" device on wheels, could/will replace 6 to 10 weeks of radiation therapy after a mastectomy or lumpectomy.

12/05/2017 Webcast Presentation
http://wsw.com/webcast/ldmicro13/srts/index.aspx



The information posted by 2morrowsGains is opinion only and should not to be taken as investment advice.
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist